273 related articles for article (PubMed ID: 26444103)
1. Use of Immunomodulators and Biologics Before, During, and After Pregnancy.
McConnell RA; Mahadevan U
Inflamm Bowel Dis; 2016 Jan; 22(1):213-23. PubMed ID: 26444103
[TBL] [Abstract][Full Text] [Related]
2. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease.
Saha S; Wald A
Expert Opin Drug Saf; 2012 Nov; 11(6):947-57. PubMed ID: 22954378
[TBL] [Abstract][Full Text] [Related]
4. Biologics and pregnancy: a clinician's guide to the management of IBD in pregnant women.
Guerrero Vinsard D; Kane SV
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):633-641. PubMed ID: 33440996
[No Abstract] [Full Text] [Related]
5. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
Moens A; van der Woude CJ; Julsgaard M; Humblet E; Sheridan J; Baumgart DC; Gilletta De Saint-Joseph C; Nancey S; Rahier JF; Bossuyt P; Cremer A; Dewit S; Eriksson C; Hoentjen F; Krause T; Louis E; Macken E; Milenkovic Z; Nijs J; Posen A; Van Hootegem A; Van Moerkercke W; Vermeire S; Bar-Gil Shitrit A; Ferrante M
Aliment Pharmacol Ther; 2020 Jan; 51(1):129-138. PubMed ID: 31692017
[TBL] [Abstract][Full Text] [Related]
6. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding.
Gisbert JP
Inflamm Bowel Dis; 2010 May; 16(5):881-95. PubMed ID: 19885906
[TBL] [Abstract][Full Text] [Related]
7. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study.
Kanis SL; de Lima-Karagiannis A; de Boer NKH; van der Woude CJ
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1232-1241.e1. PubMed ID: 28342949
[TBL] [Abstract][Full Text] [Related]
8. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease.
Mahadevan U; McConnell RA; Chambers CD
Gastroenterology; 2017 Feb; 152(2):451-462.e2. PubMed ID: 27769809
[TBL] [Abstract][Full Text] [Related]
9. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.
Gisbert JP; Chaparro M
Am J Gastroenterol; 2013 Sep; 108(9):1426-38. PubMed ID: 23752881
[TBL] [Abstract][Full Text] [Related]
10. Drug therapy of inflammatory bowel disease in fertile women.
Kroser J; Srinivasan R
Am J Gastroenterol; 2006 Dec; 101(12 Suppl):S633-9. PubMed ID: 17177868
[TBL] [Abstract][Full Text] [Related]
11. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis.
Gubatan J; Nielsen OH; Levitte S; Juhl CB; Maxwell C; Streett SE; Habtezion A
Am J Gastroenterol; 2021 Feb; 116(2):243-253. PubMed ID: 33110017
[TBL] [Abstract][Full Text] [Related]
12. The use of biologic agents in pregnancy and breastfeeding.
Horst S; Kane S
Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
[TBL] [Abstract][Full Text] [Related]
13. The use of biologic therapy in pregnancy: a gastroenterologist's perspective.
Hassid B; Mahadevan U
Curr Opin Rheumatol; 2014 May; 26(3):347-53. PubMed ID: 24625373
[TBL] [Abstract][Full Text] [Related]
14. [Pregnancy and inflammatory bowel disease: experience in 17 patients].
Vergara A MT; Rey G P
Rev Med Chil; 2011 Nov; 139(11):1421-7. PubMed ID: 22446646
[TBL] [Abstract][Full Text] [Related]
15. Management of inflammatory bowel disease in the pregnant patient.
Habal FM; Ravindran NC
World J Gastroenterol; 2008 Mar; 14(9):1326-32. PubMed ID: 18322943
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications.
McConnell RA; Mahadevan U
Gastroenterol Clin North Am; 2016 Jun; 45(2):285-301. PubMed ID: 27261899
[TBL] [Abstract][Full Text] [Related]
17. From conception to delivery: managing the pregnant inflammatory bowel disease patient.
Huang VW; Habal FM
World J Gastroenterol; 2014 Apr; 20(13):3495-506. PubMed ID: 24707132
[TBL] [Abstract][Full Text] [Related]
18. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
[TBL] [Abstract][Full Text] [Related]
19. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Ward MG; Irving PM; Sparrow MP
World J Gastroenterol; 2015 Oct; 21(40):11331-42. PubMed ID: 26525434
[TBL] [Abstract][Full Text] [Related]
20. Continuing immunomodulators and biologic medications in pregnant IBD patients - pro.
Mahadevan U
Inflamm Bowel Dis; 2007 Nov; 13(11):1439-40. PubMed ID: 17763475
[No Abstract] [Full Text] [Related]
[Next] [New Search]
